A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Trial Profile

A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Dexamethasone (Primary) ; Venetoclax (Primary)
  • Indications Amyloid light-chain amyloidosis
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 26 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top